INmune Bio, Inc. (INMB) — Financial statements
Income statement, balance sheet, and cash flow for INmune Bio, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.05↑257.1% | 0.01↓91.0% | 0.16↓58.6% | 0.37↑106.6% | 0.18 | |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | 0.05↑257.1% | 0.01↓91.0% | 0.16↓58.6% | 0.37↑106.6% | 0.18 | |
| Operating Expenses | ||||||
| R&D Expenses | 21↓37.7% | 33↑63.6% | 20↑18.8% | 17↓16.9% | 21 | |
| General & Administrative Expenses | 10↑8.2% | 9↓1.5% | 10↑3.9% | 9↑5.3% | 9 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 10↑8.2% | 9↓1.5% | 10↑3.9% | 9↑5.3% | 9 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 31↓27.5% | 43↑42.7% | 30↑13.6% | 26↓10.3% | 29 | |
| Total Costs & Expenses | 31↓27.5% | 43↑42.7% | 30↑13.6% | 26↓10.3% | 29 | |
| Operating Results | ||||||
| Operating Income | -31↑27.6% | -43↓43.4% | -30↓14.6% | -26↑11.0% | -29 | |
| Depreciation & Amortization | 0.08↓84.8% | 0.55↓98.1% | 30↑14.6% | 26↓11.0% | 29 | |
| EBITDA | -31↑26.8% | -42 | 0.00 | 0.00 | 0.00 | |
| EBIT | -31↑27.6% | -43↓43.4% | -30↓14.6% | -26↑11.0% | -29 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.85 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Interest Income | 0.85 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Income / Expenses | -15↓2824.1% | 0.55↑307.1% | -0.27↑80.2% | -1↓13.6% | -1 | |
| Income Before Tax | -46↓9.2% | -42↓40.2% | -30↓9.9% | -27↑10.0% | -30 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -46↓9.2% | -42↓40.2% | -30↓9.9% | -27↑10.0% | -30 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -46↓9.2% | -42↓40.2% | -30↓9.9% | -27↑10.0% | -30 | |
| Bottom-Line Net Income | -46↓9.2% | -42↓40.2% | -30↓9.9% | -27↑10.0% | -30 | |
| EPS (Basic) | -1.86↑11.8% | -2.11↓26.3% | -1.67↓9.9% | -1.52↑19.1% | -1.88 | |
| EPS (Diluted) | -1.86↑11.8% | -2.11↓26.3% | -1.67↓9.9% | -1.52↑19.1% | -1.88 | |
| Weighted Average Shares | 27↑33.3% | 20↑10.9% | 18↑0.3% | 18↑11.1% | 16 | |
| Weighted Average Diluted Shares | 27↑33.3% | 20↑10.9% | 18↑0.3% | 18↑11.1% | 16 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.